Elite Sponsors

Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc. is a publicly traded pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Rhopressa has been approved by the FDA and Aerie expects to launch the product by mid-second quarter 2018. The company is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research and development agreement with Royal DSM NV. Aerie Pharmaceuticals, Inc. was founded in 2005 and is based in Irvine, California.


Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. Through Surgical, Pharmaceutical and Vision Care, Alcon offers the world’s widest spectrum of ophthalmic products, helping millions of patients see the world better with clarity, color and beauty.

Johnson & Johnson Vision

Johnson & Johnson Vision is committed to improving and restoring sight for patients worldwide. Through their world-leading ACUVUE® Brand Contact Lenses portfolio, newly acquired cataract surgery, laser refractive surgery (LASIK) and consumer eye health businesses, they now serve more than 60 million patients a day across 103 countries. Dual headquartered in Jacksonville, Florida, and Santa Ana, California, Johnson & Johnson Vision has more than 8,400 employees worldwide.

Carl Zeiss Medical Technologies

Carl Zeiss Meditec, a world-leading medical technology company, supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete solutions for diagnosis and treatment of eye diseases, innovative visualization solutions for microsurgery, and promising, future-oriented technologies such as intraoperative radiotherapy.

Premier Sponsor


As a global ophthalmology company, Santen specializes in the research, development and commercialization of pharmaceutical, surgical, and OTC eye care products. With over 3,400 employees and its worldwide headquarters in Japan, Santen continues to provide innovative solutions in glaucoma, retina, uveitis, dry eye, ocular allergy and infection to patients around the world.


Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions.

Major Sponsors


Allergan (NYSE: AGN) is a unique, global pharmaceutical company focused on developing, manufacturing and commercializing high quality generic and innovative branded pharmaceutical products for patients around the world.  The Company has approximately 30,000 employees worldwide and maintains global headquarters in Dublin, Ireland.

Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight. Bausch + Lomb is a global hallmark for innovation and quality, offering the widest and finest range of eye health products including ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments.

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 3 FDA-approved sustained-release treatments in ophthalmology. In addition, DEXYCU (dexamethasone intraocular suspension) 9% was approved by U.S. Food and Drug Administration (FDA) on February 9, 2018.


Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products.

Piper Jaffray

Piper Jaffray (NYSE: PJC) is a leading investment bank focused on mergers and acquisitions, public offerings, public finance, institutional brokerage, investment management and research. Founded in 1895, the firm is headquartered in Minneapolis with offices across the U.S. and in London, Aberdeen, Zurich and Hong Kong. Learn more at piperjaffray.com.

Sun Pharmaceutical Industries

Sun Ophthalmics is reenergizing eye care. We are a US division of Sun Pharma, a global specialty pharmaceutical corporation with operations in over 150 countries. We focus on your needs as a professional, offering support so you can focus on your patients. Discover a brighter future in eye care.

Innovation Sponsors


AcuFocus, an ophthalmic medical device company, develops and markets small aperture products. The KAMRA® inlay and the IC-8® IOL are designed to provide patients with a true extended range of vision. The KAMRA inlay is the first FDA approved corneal inlay. The IC-8 IOL is not approved in the U.S.


Avedro is a privately held pharmaceutical and medical device company advancing the science and technology of corneal cross-linking and refractive correction.


Cassini pioneers smart and highly accurate corneal diagnostic solutions that are affordable, fast and user-friendly, providing care providers worldwide with advanced technology that best serves their patients.

Cassini helps cataract surgeons to better understand properties of the total corneal in order to improve outcomes and increase premium patient satisfaction and volume. Cassini offers a full suite of examinations required for toric, extended depth of focus and multifocal IOL implantation, including corneal topography, posterior corneal analysis, mesopic and photopic pupillometry and full color photography. The technology employs red, green yellow and infrared LEDs that are positioned in unique relationships, giving each one a GPS-like coordinate. Cassini employs the ray-tracing principle to measure relative position, using the color LEDs as triangulation points.


Ellex works with leading physicians, technical institutions and universities to discover, develop and deliver new ways to treat of some of the world’s most prevalent eye conditions. Initially with SLT Selective Light Therapy, then through our 2RT® Retinal Rejuvenation Therapy, and more recently with the introduction of iTrack™ — our solution for minimally invasive glaucoma surgery (MIGS) — we’re expanding our focus on the development of restorative, rejuvenative treatment options that work holistically with the body’s natural healing ability.


Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma. Glaukos has developed the iStent®, iStent inject® and iStent supra® technologies which are designed to reduce IOP and dependence on ocular hypotensive medications in patients with mild-to-moderate open-angle glaucoma. The iStent®, iStent inject are CE marked with availability in selected markets around the world. The iStent Trabecular Micro-Bypass Stent is FDA approved in the USA. iStent inject and iStent supra are under clinical investigation in the USA.

Kala Pharmaceuticals

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYSTM (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which an NDA has been accepted for review by the FDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.



With our sensors, furnished with an abundance of chemistries, we can accurately identify and quantify a whole suite of ophthalmic disorders such as inflammation(MMP-9), Adenovirus,Tryptase, etc. Discuss bench and clinical data using the advanced stage of development of LacriPen, positioning it as the most versatile diagnostic technology SPR, in the industry.

Lagunita Biosciences

Lagunita Biosciences is a healthcare investment company and incubator that creates and grows early stage companies to commercialize impactful translational science that addresses significant clinical needs. We evaluate opportunities in five key areas that correspond to the strengths and expertise of our team and network: Ophthalmology, protein engineering & drug discovery, surgical devices, optical diagnostics and therapeutics and mobile health.


Nicox is an international ophthalmic company, with two out-licensed commercial-stage products, developing innovative solutions to help maintain vision and improve ocular health. The Company’s strategy is to maximise the potential of its proprietary nitric oxide (NO)-donating research platform and its products and product candidates through in-house development and industry-leading collaborations.


PowerVision has developed a fluid-controlled accommodating IOL designed to restore youthful vision. The FluidVision® AIOL provides True Accommodation™ by mimicking the eye’s natural accommodative process to transport fluids inside it, creating true shape change. The Company has shown in clinical trials that it can deliver clear vision at all distances.

Refocus Group

Refocus Group Inc., is a pioneer in vision-correction technology and the developer of the VisAbility™ Micro Insert System designed to restore the full natural accommodative reflex of the presbyopic patient. The procedure is performed outside the visual axis, thereby preserving the patient's quality of vision at all distances. The VisAbility™ Micro Insert System is currently undergoing a US IDE Multi-Center Trial through Refocus Group Inc., Dallas, TX. The device is CE marked and available in Europe through Refocus Ocular B.V., Netherlands.

Sight Sciences

In 2011, Sight Sciences was founded to change the way the practice of ophthalmology and optometry thinks about and treats the leading causes of eye disease. Supported by leading medical technology and private equity investors, Sight Sciences operates two business lines: surgical and non-surgical systems. Its surgical product portfolio consists of the OMNI™ Surgical System, TRAB®360 and VISCO360® for use by ophthalmologists. Its non-surgical product portfolio consists of its TearCare™ technologies for use by ophthalmologists and optometrists.

SightGlass Vision

SightGlass Vision, Inc., a clinical stage, start-up biotech/medical device company based in Menlo Park, CA. SightGlass is developing innovative spectacle lenses to reduce progression of myopia in children. Based on research at the University of Washington, SightGlass was founded in 2016 by Prof. Jay Neitz and Prof. Maureen Neitz, world-renowned vision researchers, and Dr. Thomas Chalberg, a serial entrepreneur in the biotechnology and medical device sectors. Myopia is rising rapidly around the world, and by 2050, approximately 5 billion people will be myopic. SightGlass's mission is to reduce myopia progression for millions of children suffering from myopia around the world.

SightLife Surgical

SightLife Surgical is committed to transforming the complex corneal environment to provide better products and streamlined services for surgeons. Which in turn, will help more people see the world through new eyes. We make more corneas available for transplant than any other company in the world.

Trial Runners

Trial Runners is an ophthalmology CRO providing biotech and pharmaceutical companies with clinical research management services. During the past 9 years, we have worked on over 50 clinical studies researching innovative ways to manage or cure diseases related to the eye.

Mynosys Cellular Devices

The ZeptoTM Capsulotomy System provides surgeons of all skill levels an inexpensive, easy to use, automated method for producing high quality anterior lens capsulotomies. ZeptoTM integrates seamlessly into the cataract surgery routine, and its unique clinical and device characteristics make it an attractive product in growing cataract surgery market worldwide.

Founding Sponsors


Clarus is a global investment firm dedicated to life sciences. Founded in 2005, our Portfolio includes public and private companies in the biotechnology and healthcare diagnostic sectors. Clarus is presently managing $2.6 billion.

InterWest Partners

For over 37 years InterWest has partnered with entrepreneurs to build award winning healthcare and technology companies. As we complete investing InterWest X, a $650M fund, we continue to believe that providing capital is just the beginning of a long-term collaboration with entrepreneurs to turn their vision into a thriving company.

Versant Ventures

Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $1.9 billion under management and offices in North America and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, nearly 50 Versant companies have achieved successful acquisitions or IPOs.

Media Partners

Bryn Mawr Communications

Bryn Mawr Communications’ (BMC) eye care publications are uniquely positioned in ophthalmology to serve both physicians’ and industry’s needs.

Cataract & Refractive Surgery Today, Cataract & Refractive Surgery Today Europe, Glaucoma Today, Retina Today, MillennialEYE, and CollaborativeEYE showcase in-depth coverage of surgical approaches, device development, pharmacologic innovations, industry trends, and practice management.

By partnering with key opinion leaders, BMC’s eye care publications balance institutional wisdom with fresh perspectives through print magazines, an expansive video library, and timely news feeds. BMC’s in-house production team brings information directly to physicians through live meetings, simulcasted symposia, live surgeries, and more.


The mission of Ethis, Inc., is to facilitate global innovation in eyecare by providing strategic analysis, exceptional content across a wide range of media, and an extensive network of key ophthalmic and optometric opinion leaders to our industry and academic partners around the world.


As the news and feature magazine of the American Society of Cataract & Refractive Surgery, EyeWorld serves as the premier publication for anterior segment surgeons. The magazine provides comprehensive ophthalmic news and the latest clinical information in the areas of cataract, refractive, cornea, glaucoma, and retina. Each article is carefully reviewed by the editorial staff and the article’s sources before publication. EyeWorld Meeting Reporter/Video Reporter is produced live onsite and contains information on the latest cutting-edge technologies and techniques in the ophthalmic industry. The EyeWorld Education Hub is a new way to view content. Simply choose a disease state to view surgical videos, symposia, webinars, clinical interviews, and articles on that topic.

Market Scope

Market Scope is the leading source for market data, independent perspective, and objective analysis in today’s ophthalmic marketplace.

Market Scope surveys ophthalmologists regarding procedure volumes, surgical techniques, and product use. This data, along with an extensive database, wide-ranging knowledge of ophthalmic products and technology, and comprehensive network of industry contacts, is used to create more than 20 specialized, yearly reports on the ophthalmic industry.

These reports are used to measure performance, make investment decisions, and allocate resources and serve as starting points for many annual planning cycles, strategic plans, acquisition analyses, and return on investment decisions in the industry. Market Scope has been committed to ophthalmology for more than 20 years and continues to be the most highly valued source for accurate and timely information about ophthalmic markets.

Ocular Surgery News

Healio.com/OSN, the online home of Ocular Surgery News, offers daily news, physician perspectives, exclusive online content, extensive CME and more. As the best-read newspaper for ophthalmologists, Ocular Surgery News holds a unique place among eye care publications. With the largest dedicated staff focused solely on ophthalmology, OSN strives to bring our readers a deeper understanding of the news and events that affect their profession.

Ophthalmology Times

Ophthalmology Times is a physician-driven publication that disseminates news and information of a clinical, socioeconomic, and political nature in a timely and accurate manner for members of the ophthalmic community. With clinical coverage that focuses on cutting-edge advancements in surgery, drug therapies, technology, and clinical diagnosis and an unparalleled engagement of over 300,000 touchpoints per month, Ophthalmology Times is a one-stop information resource for ophthalmologists.


US Ophthalmic Review is a peer-reviewed, open access, bi-annual journal specializing in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of ophthalmology.

The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting, enabling time-pressured physicians to stay abreast of key advances and opinion in ophthalmic practice in the US.

Guided by an Editorial Board comprising world-renowned experts in their respective sub-specialties, the journal's editorial policy is designed to promote best practice and encourage discussion among practicing professionals in the field.

Supporting Organizations

Glaucoma Research Foundation

Glaucoma Research Foundation (GRF) is a national nonprofit founded in 1978 in San Francisco to encourage innovative research toward better treatments for people with glaucoma. GRF has funded more than $60 million of grants and projects in 40 years. In addition to advancing innovation in glaucoma research, GRF provides education and support for people with glaucoma and sponsors catalyst meetings like the annual Glaucoma 360 New Horizons Forum to foster collaboration and speed the cure. The Glaucoma Research Foundation mission is to prevent vision loss from glaucoma by investing in innovative research, education, and support with the ultimate goal of finding a cure.


Advancing Diversity in Leadership. OWL is a 900+ member professional organization focused on leadership development. Our mission is to promote and develop diverse leadership to advance Ophthalmic Innovation and Patient Care. We hold local "OWL Connect" events, online learning sessions and Signature Events at ASCRS and AAO.


Get the Latest News, Podcasts and Videos.